Lupin receives USFDA approval for Divalproex Sodium extended-release tablets

Lupin has received USFDA approval for its generic Divalproex Sodium extended-release tablets to market the same in the American market.

The drug Divalproex Sodium extended-release tablets will be made available in the strengths of 250 mg and 500 mg. It may be noted that, is a generic version of AbbVie Inc’s Depakote extended-release tablets in the same strengths.

The drug is prescribed for treatment of manic or mixed episodes associated with bipolar disorder with or without psychotic features, prophylaxis of migraine headaches and for treatment of complex partial seizures and simple and complex absence seizures.

According to market estimates, Divalproex sodium extended-release (ER) tablets USP, 250 mg and 500 mg had annual sales of approximately USD 159 million (over Rs 1,100 crore) in the US.

Company Profile : Lupin Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.